Get started
djh860

LGND is at the bottom of its range earnings reoprt 2/16/22

Long
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)  
djh860  
NASDAQ:LGND   Ligand Pharmaceuticals Incorporated
Trend Analysis
0
0
trendanalysis
they last reported sales were up 59% and profits were FAT because most of their revenues are from royalties so cost of sales is near zero.
This looks like a reasonable spot to buy in front of earnings.
www.earningswhispers....com/epsdetails/lgnd
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.